Clinical Trial News and Research

RSS

New antibody combination shows 'surprising' results in high-risk follicular lymphoma trial

Researchers conducting a Phase 2 clinical trial at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine say a new combination of antibody therapies produced a 'surprisingly high' response rate in patients with high-risk follicular lymphoma, a type of non-Hodgkin lymphoma.

11 Dec 2023

Tirzepatide maintains weight loss and improves cardiometabolic health in SURMOUNT-4 trial

The current class of anti-obesity drugs is proving remarkably effective at removing excess pounds. However, a phase 3 randomized clinical trial led by researchers at Weill Cornell Medicine and NewYork-Presbyterian found that people who stopped taking the medication regained much of that weight within a year.

11 Dec 2023

Double punch for B-cell lymphomas: CAR T-cell innovation boosts efficacy, cuts toxicity

The Malaghan Institute of Medical Research in collaboration with Wellington Zhaotai Therapies Limited today announced results of its phase 1 dose escalation trial of a new third-generation anti-CD19 chimeric antigen receptor (CAR) T-cell therapy to be presented at the American Society of Hematology (ASH) Annual Meeting in San Diego on 11 December, 3pm.

11 Dec 2023

Ketogenic diet proved to be effective at controlling polycystic kidney disease

It's official: The ketogenic diet proved to be effective at controlling polycystic kidney disease (PKD) in the first randomized controlled clinical trial of ketogenic metabolic therapy for PKD.

11 Dec 2023

UMSOM receives $29 million research award to improve health outcomes in people who inject opioid drugs

University of Maryland School of Medicine Dean Mark T. Gladwin, MD, announced today that the school will receive a $29 million research award over four years from the National Institutes of Health to lead a multicenter trial that aims to improve health outcomes in people who inject opioid drugs and are hospitalized with infectious complications of their drug use.

11 Dec 2023

Quizartinib extends life and enhances wellbeing for AML patients with key mutation

In a study led by researchers at Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine, patients recently diagnosed with a common and aggressive form of acute myeloid leukemia reported having improved quality of life when a newly approved drug was part of the treatment plan.

11 Dec 2023

Transcendental Meditation significantly reduces PTSD, anxiety, and burnout in nurses during COVID-19

Frontline nurses who learned the Transcendental Meditation technique during the COVID-19 pandemic showed rapid and significant improvements in flourishing, PTSD, anxiety, and burnout over 3 months compared to controls, according to a study published today in the Journal of Nursing Administration.

11 Dec 2023

Study could pave the way for synergistic therapeutic combinations to better treat SF3B1-mutant MDS

A new study from researchers with Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine and collaborating organizations provides insight into the underlying mechanisms of gene mutations commonly seen in patients with myelodysplastic syndromes (MDS) and other myeloid neoplasms.

11 Dec 2023

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

Two clinical trials led by researchers from The University of Texas MD Anderson Cancer Center demonstrated early positive results from novel therapies targeting menin for the treatment of relapsed or refractory acute leukemias with specific genetic alterations.

11 Dec 2023

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combining the JAK inhibitor ruxolitinib with the BCL-xL inhibitor navitoclax was twice as effective in reducing enlarged spleens – a major indicator of clinical improvement – compared with standard-of-care ruxolitinib monotherapy for adult patients with intermediate or high-risk myelofibrosis, a rare bone marrow cancer, according to results of the Phase III TRANSFORM-1 trial reported by researchers from The University of Texas MD Anderson Cancer Center.

11 Dec 2023

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Older patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) who were not good candidates for the standard treatment of intensive chemotherapy had a median overall survival (OS) of 6.5 years on an alternate regimen of dasatinib and blinatumomab.

11 Dec 2023

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

Early results from a Phase I clinical trial of AT101, a new CAR T cell therapy that uses a distinct binding mechanism to target CD19, show a 100 percent complete response (CR) rate at the higher dose levels studied in the trial, according to researchers from the University of Pennsylvania Perelman School of Medicine and Penn Medicine's Abramson Cancer Center.

11 Dec 2023

The influence of vitamin supplementation on longitudinal patterns of maternal vitamin status from preconception to post-delivery

Researchers secondary analyzed the NiPPeR randomized clinical trial (RCT) data to assess maternal vitamin levels pre-conception, during pregnancy, and post-delivery and also explored the impact of vitamin supplementation before and during gestation.

11 Dec 2023

Groundbreaking online community connects Progeria patients worldwide

A ground-breaking online community has been launched to allow people with the rare disease Progeria to communicate regardless of their location or language.

11 Dec 2023

Low-risk DCIS patients may safely skip radiotherapy after surgery, study finds

Patients with low-risk ductal carcinoma in situ (DCIS) who skipped adjuvant radiotherapy after breast-conserving surgery had comparable five-year outcomes to those with high-risk DCIS who received adjuvant radiotherapy, according to results from the E4112 clinical trial presented at the San Antonio Breast Cancer Symposium, held December 5-9, 2023.

8 Dec 2023

Less than five minutes of daily physical activity could prolong life in people with inoperable lung cancer

Lung cancer kills more people globally each year than any other type of cancer, however new Curtin University-led research has found less than five minutes of daily physical activity could be linked with prolonged life in people living with inoperable forms of the disease.

7 Dec 2023

Vanderbilt's potential schizophrenia treatment enters phase 1 clinical trials

A potential schizophrenia treatment discovered through the Warren Center for Neuroscience Drug Discovery has been cleared by the U.S. Food and Drug Administration for use in phase 1 clinical trials - the third WCNDD therapeutic to reach that benchmark.

7 Dec 2023

Researchers discover how bexmarilimab activates immune cells against tumors

Researchers at the University of Turku, Finland, have uncovered how the new bexmarilimab therapy alters the function of immune cells so that they can infiltrate the tumor in cancer patients who do not respond to any other current therapies.

7 Dec 2023

Cocoa extract may benefit cognitive function in older adults with poor diets

Cocoa extract has shown a potential protective effect on cognition but randomized clinical trials in older adults have had inconsistent results.

7 Dec 2023

New early phase study evaluates “on-demand” HIV prevention method for women

A fast-dissolving vaginal insert that women would use at or around the time of sex as an "on-demand" HIV prevention method is being evaluated in a new early phase study being conducted by MATRIX, a United States Agency for International Development (USAID)-funded project focused on the early research and development of innovative HIV prevention products for women.

7 Dec 2023

Clinical Trial News and Research

New antibody combination shows 'surprising' results in high-risk follicular lymphoma trial

Tirzepatide maintains weight loss and improves cardiometabolic health in SURMOUNT-4 trial

Double punch for B-cell lymphomas: CAR T-cell innovation boosts efficacy, cuts toxicity

Ketogenic diet proved to be effective at controlling polycystic kidney disease

UMSOM receives $29 million research award to improve health outcomes in people who inject opioid drugs

Quizartinib extends life and enhances wellbeing for AML patients with key mutation

Transcendental Meditation significantly reduces PTSD, anxiety, and burnout in nurses during COVID-19

Study could pave the way for synergistic therapeutic combinations to better treat SF3B1-mutant MDS

MD Anderson researchers report early success of novel menin-targeted therapies in leukemia

New drug combination doubles effectiveness in shrinking enlarged spleens in myelofibrosis patients

Combination of dasatinib and blinatumomab offers effective treatment for older Ph+ ALL patients

Phase I clinical trial of new CAR T cell therapy AT101 shows promising early responses

The influence of vitamin supplementation on longitudinal patterns of maternal vitamin status from preconception to post-delivery

Groundbreaking online community connects Progeria patients worldwide

Low-risk DCIS patients may safely skip radiotherapy after surgery, study finds

Less than five minutes of daily physical activity could prolong life in people with inoperable lung cancer

Vanderbilt's potential schizophrenia treatment enters phase 1 clinical trials

Researchers discover how bexmarilimab activates immune cells against tumors

Cocoa extract may benefit cognitive function in older adults with poor diets

New early phase study evaluates “on-demand” HIV prevention method for women

eBook: Using iPSCs models for human disease research and drug discovery eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer